Premium
New multiple‐agent chemotherapy (B‐DOPA) for advanced Hodgkin's disease
Author(s) -
Lokich Jacob J.,
Frei Emil,
Jaffe Norman,
Tullis James
Publication year - 1976
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197608)38:2<667::aid-cncr2820380207>3.0.co;2-1
Subject(s) - medicine , vincristine , prednisone , regimen , chemotherapy , refractory (planetary science) , cyclophosphamide , gastroenterology , surgery , combination chemotherapy , physics , astrobiology
B‐DOPA (Bleomycin (B), D‐imidazole carboxamide (D), Oncovin (O), Prednisone (P), Adriamycin (A) is a program developed for the treatment of Hodgkin's disease resistant to MOPP therapy. Twenty unselected patients were treated by the following dose schedule: B, 4 mg/m 2 days 2 and 5; D, 150 mg/m 2 days 1 to 5; O (vincristine), 1.5 mg/m 2 days 1 and 5; P, 40 mg/m 2 days 1 to 6; A, 60 mg/m 2 day 1. Each course, was repeated at 3 to 4 week intervals to maximum adriamycin dose of 450 mg/m 2 . All patients had received prior MOPP therapy and six had received prior radiotherapy. Fifteen of the 20 patients entered into the study were evaluable for response. There were nine (60%) complete responders and three (20%) partial responders. The median duration of complete remission was 14+ months with six of nine patients remaining in remission to a maximum of 21 months. The median survival of the nonresponders was 3 months. B‐DOPA is an effective combination chemotherapy regimen for advanced Hodgkin's disease in patients who have previously received MOPP treatment, including patients who are refractory to MOPP therapy. The B‐DOPA program, or modifications thereof, may be integrated into primary treatment programs for advanced Hodgkin's disease.